Please check your internet connection and try again.
# Tabovoihep
## Overview
Tabovoihep is a brand name for a medication containing pegylated interferon alfa-2a. It is a recombinant protein that mimics the body's natural interferon response.
## Primary Indications
* Hepatitis C (in combination with other agents)
* Hepatitis B
## Adult Dosing
* **Hepatitis C:** 180 mcg subcutaneously once weekly for 48 weeks (in combination therapy).
* **Hepatitis B:** 180 mcg subcutaneously once weekly for at least 48 weeks.
## Pediatric Dosing
* **Hepatitis B:** Dosing in pediatric patients is not well-established and should be determined by a specialist.
## Dose Adjustments
* **Hematologic Abnormalities:** Dose reduction may be necessary for neutropenia, thrombocytopenia, or anemia. Refer to specific clinical guidelines for threshold values and reduction schedules.
* **Hepatic Impairment:** Dose reduction may be necessary in patients with decompensated cirrhosis.
## Contraindications
* Hypersensitivity to peginterferon alfa-2a, interferon alfa, or any component of the formulation.
* Autoimmune hepatitis.
* Decompensated cirrhosis.
* Severe depression or suicidal ideation.
* Uncontrolled hyperthyroidism or other uncontrolled endocrine disorders.
## Adverse Effects
Common adverse effects include fatigue, influenza-like symptoms (fever, chills, headache, myalgia), injection site reactions, depression, insomnia, nausea, diarrhea, and hair loss. Serious adverse effects can include severe psychiatric disturbances (depression, suicidal ideation), autoimmune disorders, severe hematologic abnormalities, and thyroid dysfunction.
## Key Drug Interactions
* **Theophylline:** Peginterferon alfa-2a may decrease theophylline clearance, requiring monitoring of theophylline levels and potential dose adjustments.
* **Zidovudine:** May increase zidovudine levels, increasing the risk of toxicity.
* **Ribavirin:** Concurrent use with ribavirin (for Hepatitis C) requires careful monitoring due to potential for additive hematologic toxicity (anemia). Specific dosing regimens are critical.
## Monitoring
* Complete blood counts (CBC) with differential and platelet count.
* Liver function tests (ALT, AST, bilirubin).
* Thyroid function tests (TSH).
* Assays for Hepatitis B virus DNA or Hepatitis C virus RNA.
* Psychiatric status.
## Clinical Pearls
* Administer subcutaneous injections in the abdomen or thigh.
* Rotate injection sites.
* Patients should be counseled on potential psychiatric side effects and instructed to report any mood changes or suicidal thoughts immediately.
* Ensure adequate hydration and management of influenza-like symptoms.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions. Dosing and management may vary based on individual patient factors and local protocols.*
